Lymphoma: all 5,624 studies
Page 29 of 57. Open to participants first (824), then studies with results posted, then the rest; newest registration first within each.
- DOLPHIN-VIVO: Diagnosis Of LymPHoma IN Vivo (Ex Vivo Phase)CompletedNCT04162431
- CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell MalignanciesStatus unknownNCT04162340Phase 1
- TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin LymphomaTerminatedNCT04161118Phase 2
- Use of a Patient Preferences Shared Decision-Making Encounter Tool in Clinical Practice for Patients With DLBCL and FLCompletedNCT04160442Not applicable
- The Clinical Implications of Immune Checkpoint Pathways in PCNSLCompletedNCT04158128
- Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular LymphomaTerminatedNCT04156828Phase 1
- Non-invasive Evaluation of Lymphoma Patients Based on Artificial Intelligence and PET/MRIStatus unknownNCT04154228Not applicable
- A Phase I Clinical Trial of BAT4306F on Safety, Tolerability and Pharmacokinetics for PatientsCompletedNCT04152148Phase 1
- Lenalidomide Monotherapy in R/R DLBCLCompletedNCT04150328
- Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3)WithdrawnNCT04148742Phase 1/2
- NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin LymphomaCompletedNCT04136756Phase 1
- CAR-37 T Cells in Hematologic MalignanciesCompletedNCT04136275Phase 1
- Study of PD-1 Monoclonal Antibody in Combination With Chemotherapy in Patients With RR NHLStatus unknownNCT04134247Phase 4
- Bendamustine Plus Rituximab for Mantle Cell Lymphoma: a Multicenter Retrospective Analysis(BR-MCL)Status unknownNCT04127916
- ASTRAL- a Clinical Study to Assess the Efficacy and Toxicity of High-dose ChemotherapyCompletedNCT04121507Phase 2
- R2-MTX With Lenalidomide Maintenance in Newly-diagnosed PCNSL：a Multicenter Phase Ib/II StutyStatus unknownNCT04120350Phase 1/2
- Feasibility and Accuracy of Nanosensor-based Cancer Diagnosis at the Point-of-care (Chedza)CompletedNCT04119154Not applicable
- Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma.Status unknownNCT04118868Phase 1
- ctDNA and Metabolites in CSF as Early Biomarkers of Secondary CNS Involvement in Diffuse Large B-cell LymphomaStatus unknownNCT04112238
- Lenalidomide Observational Study in Patients With Mantle Lymphoma in Relapse/Refraction. Spanish Programme RRMCL Results.Status unknownNCT04109872
- A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell LymphomaStatus unknownNCT04108325Phase 1
- A Study of MIL62 in Treatment of CD20 Positive B-cell LymphomasCompletedNCT04103905Phase 1
- Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/LymphomaCompletedNCT04102150Phase 2
- Anti-PD-1 Antibody Combined With Pegaspargase in the Treatment of Advanced Stage NK/T-cell LymphomaStatus unknownNCT04096690Phase 2
- Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin LymphomaCompletedNCT04094142Phase 2
- Observational Study of CLL/SLL Treatment and Ibrutinib Treatment of CLL/SLL in Routine Clinical PracticeStatus unknownNCT04094051
- Combination of Nivolumab and DHAP in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (Nivo-DHAP)CompletedNCT04091490Phase 2
- Frequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Patients and Their Primary CaregiversActive, not recruitingNCT04090619
- Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin LymphomaCompletedNCT04089527Phase 1
- CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins LymphomaActive, not recruitingNCT04089215Phase 2
- CD22-CAR T Cells in Children and Young Adults With B Cell MalignanciesCompletedNCT04088864Phase 1
- Indocyanine Green (ICG) Guided Tumor ResectionCompletedNCT04084067Phase 1
- Cost-Effectiveness Study of PEG-rhG-CSF in Prophylactic Treatment of Neutropenia After Chemotherapy in LymphomaStatus unknownNCT04083079Phase 4
- Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System LymphomaStatus unknownNCT04083066Phase 4
- A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin LymphomaTerminatedNCT04082936Phase 1/2
- Survivorship Care Plans and Telehealth Education for the Improvement of Access to Cancer Survivorship, the IMPACT StudyCompletedNCT04081779Not applicable
- A Clinical Trial of BP1002 in Patients With Advanced Lymphoid MalignanciesActive, not recruitingNCT04072458Phase 1
- Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic CancersTerminatedNCT04072393Not applicable
- A Registry Study in Lymphoma Patients Treated With Liposomal DoxorubicinStatus unknownNCT04069845
- IBER Salvage Treatment Followed by Ibrutinib Maintenance for Relapsed or Refractory PCNSLStatus unknownNCT04066920Phase 2
- Clinical Application of Liquid Biopsy for Precise Diagnosis and Prognosis in LymphomaCompletedNCT04062877
- Ibrutinib for Relapsed or Refractory Mantle Cell LymphomaCompletedNCT04061850
- A Study of Bortezomib Combined With CHEP in Peripheral T Cell LymphomaStatus unknownNCT04061772Phase 2
- Study of A-319 in Patients With Relapsed or Refractory B-cell LymphomaStatus unknownNCT04056975Phase 1
- Lymphoproliferative Disorders After Diagnosis of Childhood Acute Lymphoblastic Leukemia/LymphomaStatus unknownNCT04055558
- QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell LymphomaWithdrawnNCT04052061Phase 1
- ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)Active, not recruitingNCT04049513Phase 1
- Clinical Outcomes of Early-progressed Follicular Lymphoma in KoreaStatus unknownNCT04048395
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin LymphomaTerminatedNCT04045028Phase 1
- A Study to Evaluate the Efficacy and Safety of a Sintilimab Plus ICE Regimen Versus ICE Regimen in Classic Hodgkin's Lymphoma Patients (cHL) Who Have Failed First-line Standard ChemotherapyStatus unknownNCT04044222Phase 3
- ERK 1/2 Signaling in Ibrutinib Resistant B-cell MalignanciesWithdrawnNCT04043845Phase 1
- PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell LymphomaStatus unknownNCT04040491Phase 4
- PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell LymphomaStatus unknownNCT04038411Phase 4
- CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma.Status unknownNCT04037566Phase 1
- Treatment of Leukemia and Lymphoma in Children With Ataxia TelangiectasiaStatus unknownNCT04037189
- A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5q or Refractory/Relapsed Mantle Cell Lymphoma in KoreaCompletedNCT04036448
- A Study of C-CAR066 in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T TherapyCompletedNCT04036019Phase 1
- Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or LymphomaWithdrawnNCT04029038Phase 1/2
- FLT PET: A Pilot Study in Lymphoma PatientsCompletedNCT04028804
- γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)Status unknownNCT04028440Early Phase 1
- Cardiovascular Effects of CART Cell TherapyCompletedNCT04026737
- Clinical Efficacy of MOAP Regimen for Relapsed/Refractory cHL as a Rescue Therapy After DP RegimenStatus unknownNCT04026269Phase 1/2
- CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell LymphomaStatus unknownNCT04026100Phase 1
- A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese PatientsActive, not recruitingNCT04024696Phase 1/2
- Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma.Status unknownNCT04023916Phase 2
- FT516 in Subjects With Advanced Hematologic MalignanciesTerminatedNCT04023071Phase 1
- Nivolumab Consolidation in Older (≥ 65) Patients With Primary CNS LymphomaCompletedNCT04022980Phase 1
- Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory DLBCLCompletedNCT04022005Phase 2
- GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCLStatus unknownNCT04021992Phase 2
- CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)WithdrawnNCT04021082Phase 2/3
- ET019003-T Cells in Relapsed/Refractory CD19+ B-Cell Leukemia and LymphomaStatus unknownNCT04014894Phase 1
- Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Non-Hodgkin LymphomaStatus unknownNCT04012892Phase 1
- Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte MalignanciesStatus unknownNCT04008394Phase 1
- Whole-body MRI in Pediatric Hodgkin's LymphomaCompletedNCT04005703
- CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic LeukemiaStatus unknownNCT04004637Phase 1
- Study of TQB2450 Injection in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell LymphomaTerminatedNCT04002622Phase 2
- A Clinical Research of CD22-Targeted CAR-T in B Cell MalignanciesStatus unknownNCT03999697Phase 1
- A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory MalignanciesWithdrawnNCT03999658Phase 2
- A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid TumorsCompletedNCT03997968Phase 1/2
- Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell LymphomaActive, not recruitingNCT03995147Phase 2
- Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell LymphomaCompletedNCT03994913Phase 1/2
- Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic LeukemiaCompletedNCT03991884Phase 1
- A Safety Study of the Pan-immunotherapy in Patients With Unresectable/Metastatic Solid Tumors or LymphomasStatus unknownNCT03991559Phase 1
- Safety and Effectiveness of EBV-specific Cytotoxic T Cells for the Treatment for EBV Lymphomas or Other EBV-associated MalignanciesWithdrawnNCT03988582Phase 2
- Exosomes and Immunotherapy in Non-Hodgkin B-cell LymphomasCompletedNCT03985696Not applicable
- Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular LymphomaActive, not recruitingNCT03980171Phase 1/2
- Genomic Evaluation in Patients With Diffuse Large B Cell Lymphoma After First Relapse/ProgressionStatus unknownNCT03977623
- To Study the Concentration Level of, Doxil, and Doxorubicin at Various Time FramesStatus unknownNCT03975205Early Phase 1
- Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's LymphomaCompletedNCT03974243Phase 1/2
- The Value of Pelvic Magnetic Resonance Imaging in Detecting Bone Marrow Infiltration of LymphomaCompletedNCT03973164
- Diffusion-weighted Magnetic Resonance Imaging in Post Therapy Patients With LymphomaStatus unknownNCT03969381
- CBT on Fatigue in Survivors of Hodgkin LymphomaCompletedNCT03968250Not applicable
- Reduced IV Fluids to Improve Clearance of HDMTX in Children w/Lymphoma or Acute Lymphoblastic LeukemiaCompletedNCT03964259Phase 1
- Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic MalignanciesCompletedNCT03955783Phase 1
- Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell LymphomaStatus unknownNCT03952572Phase 3
- Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCLStatus unknownNCT03949062Phase 2
- A Study to Describe Treatment Patterns and Disease Control in Participants With cHL and sALCL in Routine Clinical Practice in the Russian FederationCompletedNCT03942263
- Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell LymphomaCompletedNCT03939182Phase 1
- Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular LymphomaCompletedNCT03939026Phase 1
- Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell LymphomaCompletedNCT03936452Phase 2